Huadong Medicine's HDM1010 Gets FDA Nod for Phase I Trial in T2D
CompanyDrug

Huadong Medicine’s HDM1010 Gets FDA Nod for Phase I Trial in T2D

Sanyou Biopharma Partners with Medicovestor to Advance Next-Gen ADCs
CompanyDeals

Sanyou Biopharma Partners with Medicovestor to Advance Next-Gen ADCs

Huahai Pharma Receives FDA Warning Letter After Inspection
Company

Huahai Pharma Receives FDA Warning Letter After Inspection

Burning Rock Reports Q1 2025 Revenue Growth and R&D Progress
Company

Burning Rock Reports Q1 2025 Revenue Growth and R&D Progress

Sinopep Allsino Partners with Vazyme to Advance Synthetic Biology
CompanyDeals

Sinopep Allsino Partners with Vazyme to Advance Synthetic Biology

CIRC and Qianlong International Collaborate to Advance BNCT and Nuclear Medicine
CompanyDeals

CIRC and Qianlong International Collaborate to Advance BNCT and Nuclear Medicine

AstraZeneca's Calquence Combo Approved by EU for CLL Treatment
CompanyDrug

AstraZeneca’s Calquence Combo Approved by EU for CLL Treatment

Bayer's CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD
CompanyDrug

Bayer’s CONFIDENCE Study Shows Kerendia and Empagliflozin Reduce UACR in T2D-CKD

Lifetech Scientific Plans RMB 150 Million Investment in AffectOR MedTech
CompanyDeals

Lifetech Scientific Plans RMB 150 Million Investment in AffectOR MedTech

OBI Pharma Partners with TegMine to Develop Antibody-Drug Conjugates
CompanyDeals

OBI Pharma Partners with TegMine to Develop Antibody-Drug Conjugates

NeoCura Bio-Medical Gains NMPA Approval for mRNA Cancer Vaccine Trial
CompanyDrug

NeoCura Bio-Medical Gains NMPA Approval for mRNA Cancer Vaccine Trial

YolTech Receives FDA Clearance for PCSK9-Targeted Base Editing Drug YOLT-101
CompanyDrug

YolTech Receives FDA Clearance for PCSK9-Targeted Base Editing Drug YOLT-101